Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Bre...(ation of our products and pipeline produ...),Health

Date:12/12/2008

ation of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

'/>"/>

SOURCE Wyeth Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Wyeth Sets Webcast and Conference Call for 2008 Fourth Quarter and Full Year Earnings
2. Wyeth to Present at the Credit Suisse Healthcare Conference
3. The Senior Citizens Leagues Comments on U.S. Supreme Court Case Wyeth v. Levine
4. Wyeth v. Levine: Preemption and The Facts
5. Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
6. Wyeth Selected for 11th Consecutive Year as One of Working Mother Magazines 100 Best Companies for Working Mothers
7. Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble
8. Wyeth to Present at the Goldman Sachs Annual Global Healthcare Conference
9. Wyeths Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
10. Wyeth to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Wyeth Holds Annual Meeting of Stockholders